BIHRPHA@EC2609A

PUXING ENERGY

STARCOIN GROUP

KNOWLEDGE ATLAS

EASY SMART GP

WORLD SUPER

XL2CSOPSMSN-U

PPS INT'L

LAP KEI ENGRG

CHINA FORTUNE

XL2CSOPSMSN

01276

600276

SONN.CVR

CS精准医

516820

159615

520690

560600

513060

159102

Hengrui Pharma and Braveheart Bio announced positive results from a Phase 2 study of HRS-1893 for obstructive hypertrophic cardiomyopathy (oHCM). The study showed significant reductions in left ventricular outflow tract gradient (LVOT-G) with minimal changes in left ventricular ejection fraction (LVEF). The treatment demonstrated a rapid onset of effect, with 89% of patients responding well to a 40 mg or 60 mg twice-daily regimen. The results support further clinical development, with plans for a global pivotal study in 2026. The treatment was well tolerated with no new safety concerns identified.

prnewswire

HENGRUI PHARMA

Hengrui Pharma

Sonnet BioTherapeutic CVR

Mustang Bio

Harvard Bioscience

Ping An CSI Medicine and Medical Device Innovation ETF

iShares Biotechnology ETF

SPDR S&P Health Equip

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Direxion S&P Biotech Bull 3X

Penghua SSE STAR Biology and Medicine ETF

Kraneshares MSCI All China H

ICBCCS SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

Tianhong CNI BIOMEDICINE ETF

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

iShares US Medical Devices

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Invesco Nasdaq Biotechnology ETF

E Fund CSI Biotechnology Theme ETF

SPDR S&P Biotech

Huaan Hang Seng Biotech ETF

09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

01093

01772

03288

01801

01339

02097

06869

06690

03986

CSPC PHARMA(01093) rose 13.85%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 10.2%. GANFENGLITHIUM(01772) rose 9.26%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 43%. PICC GROUP(01339) fell 7.18%, with a trading turnover 746.4 Million HKD, and a year-to-date fell 19.6%. MIXUE GROUP(02097) fell 4.86%, with a trading turnover 354.1 Million HKD, and a year-to-date fell 30.2%.

Top Gainers & Losers

CSPC PHARMA

GANFENGLITHIUM

HAITIAN FLAV

INNOVENT BIO

PICC GROUP

MIXUE GROUP

YOFC

HAIER SMARTHOME

GIGADEVICE

Top 5 HK Stock Gainers/Losers (>100B) (3.27)

002466

00HSI

STECH

02026

09696

002460

02513

Ganfeng Lithium rose about 9%, Hengrui Pharma rose about 8%, TIANQI LITHIUM rose about 6%, PONY-W fell about 14%, MIXUE GROUP fell about 5%, and KNOWLEDGE ATLAS fell about 2%

Wallstreetcn

Hang Seng Index

Hang Seng TECH Index

PONY-W

TIANQI LITHIUM

Ganfeng Lithium

Hang Seng Index closes up 0.38%, Hang Seng TECH Index up 0.35%

Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials

marketscreener

Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials

Hong Kong Stocks Slump as US, Iran Offer Mixed Signals; Hengrui Pharmaceuticals' Earnings Miss Estimates

Hong Kong Stocks Slump as US, Iran Offer Mixed Signals; Hengrui Pharmaceuticals' Earnings Miss Estimates

Jiangsu Hengrui Pharma Co., Ltd. released its 2025 financial report, with annual revenue of 31.629 billion yuan, a year-on-year increase of 13%; net profit of 7.711 billion yuan, an increase of 21.69%. Revenue from innovative drug sales reached 16.342 billion yuan, an increase of 26.09%. The company will distribute a cash dividend of 1.274 billion yuan, with the actual controller Sun Piaoyang receiving 255 million yuan. At the end of the reporting period, the company's total assets and net assets increased by 39.36% and 34.61%, respectively

雷帝触网

Hengrui Pharma annual revenue 31.6 billion: net profit 7.7 billion, dividend 1.27 billion, Sun Piaoyang received 250 million

159892

China's obesity drug market is set to grow to $14 billion by 2030, with at least 10 new weight-loss drugs awaiting regulatory approval following the patent expiration of Novo Nordisk's semaglutide. Notable contenders include Hengrui Medicine and Innovent Biologics, both reporting superior weight-loss results in trials. Eli Lilly is also entering the market with a $3 billion investment. The surge in approvals is supported by China's drug regulator, which approved 76 innovative drugs last year, a 58% increase from 2024. Chinese firms are expected to price their drugs lower than semaglutide.

SCMP

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Eli Lilly

Guotai CSI Hugangshen Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025

Jiangsu Hengrui Pharmaceuticals' Profit, Revenue Climb in 2025

Hengrui Pharma announced its full-year results for the year ending last December, with a revenue of RMB 31.629 billion, an increase of 13% year-on-year; net profit of RMB 7.711 billion, an increase of 21.7% year-on-year. Earnings per share were RMB 1.19, with a final dividend of RMB 2 for every 10 shares. The revenue growth was mainly attributed to the increase in sales of innovative drugs and licensing income, with a gross profit margin stable at 86.2%. The company has received approval for 24 Class 1 innovative drugs in China and expects approximately 53 innovative products to be approved in the next three years

AASTOCKS

"Performance" Hengrui Pharma's net profit last year was 7.711 billion RMB, an increase of 21.7%, with a final dividend of 20 cents

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has published its audited annual results for the year ending December 31, 2025. The report is available on the Hong Kong stock exchange and the company's website, ensuring compliance with listing rules. The board, led by Mr. Sun Piaoyang, confirmed the report's publication, detailing the company's governance structure. The latest analyst rating for the stock (HK:1276) is a Buy with a price target of HK$96.90. Jiangsu Hengrui is a major player in the Chinese pharmaceutical market, with a market cap of HK$403B.

Tip Ranks

Jiangsu Hengrui Pharmaceuticals Publishes 2025 Audited Annual Results

The US imposed a 39% tariff on imported gold bars, sparking a rally in gold stocks, with Lao Feng Xiang rising nearly 4% again. The semiconductor sector was dragged down by SMIC's Q2 net profit plunging 19%, with most stocks falling.

SMIC

SMIC HK SDR 5to1

LAOPU GOLD

ZIJIN MINING

Zijin Mining

SD GOLD

SD-GOLD

FORTIOR

Asymchem

ZHAOJIN MINING

HORIZONROBOT-W

LINGBAO GOLD

INNOSCIENCE

CE HUADA TECH

BATELAB

ZAI LAB

Zai Lab

TIGERMED

Tigermed

FRONTAGE

CHIFENG GOLD

TONGGUAN GOLD

CHI SILVER GP

HUA HONG SEMI

Hua Hong

Hot Trades in Hong Kong Stocks (8.8)｜Gold Sector Rises Across the Board on Tariff Catalysts, SMIC Leads Decline by 6%

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

3SBIO

OSL GROUP

CPIC

SUNSHINE INS

SANDS CHINA LTD

Sands China

WYNN MACAU

CR HOLDINGS

CHINA LIFE

China Life

SBP GROUP

MELCO INT'L DEV

GUOTAI JUNAN I

AIA-R

AIA Group

SJM HOLDINGS

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WUXI APPTEC

WuXi AppTec

WUXI BIO

WuXi Biologics

REMEGEN

RemeGen

DUALITYBIO-B

INNOCARE

InnoCare Pharma

AKESO

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

ZA ONLINE

POP MART

GUMING

LIANLIAN

PICC P&C

MAO GEPING

BLOKS

PING AN

Ping An Ins HK SDR2to1

Ping An

Ping An Insurance

CITIC SEC

CITIC Securities Co., Ltd.

EB SECURITIES

EBSCN

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

BIHRPHA@EC2609A(27146.HK)

BIHRPHA@EC2609A Stock Performance Chart

09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy

Top 5 HK Stock Gainers/Losers (>100B) (3.27)

Hang Seng Index closes up 0.38%, Hang Seng TECH Index up 0.35%

Hengrui Pharmaceuticals' Unit Gets Nod for HRS9531 Injection Clinical Trials

Hong Kong Stocks Slump as US, Iran Offer Mixed Signals; Hengrui Pharmaceuticals' Earnings Miss Estimates